A Caltech Library Service

Biotech leaders call for free press

Cohen, Ron and Baltimore, David (2018) Biotech leaders call for free press. Nature Biotechnology, 36 (10). pp. 920-922. ISSN 1087-0156. doi:10.1038/nbt.4271.

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item:


We, the undersigned, are biotechnology executives, entrepreneurs, academic leaders and investors. We are gravely concerned about trends in the United States that are undermining our news media, such that more than 300 news publications across the country recently found it necessary to run coordinated editorials in defense of the First Amendment's guarantee of freedom of the press. Why do we, in particular, feel compelled to speak out? We dedicate our lives to discovering and developing new medicines. In recent years, we have witnessed astonishing advances in medicine, including treating diseases at the level of genes and cells. These modern miracles rely, more than anything else, on the free and public exchange of ideas. This encompasses the ability to collaborate, debate, and test one another's ideas and findings, and to publish data regardless of political, religious or other external pressures or considerations. This is foundational to the scientific method, without which we all might still be living in caves and have an average life expectancy of 30.

Item Type:Article
Related URLs:
URLURL TypeDescription ReadCube access
Cohen, Ron0000-0002-9152-8446
Baltimore, David0000-0001-8723-8190
Additional Information:© 2018 Springer Nature Limited. Published 11 October 2018. This letter represents solely the individual and personal views of the authors and signatories, and not those of their employers, companies, universities or any other organization or agency. Competing interests: John Maraganore is CEO and board member of Alnylam Pharmaceuticals, and on the board of Agios Pharmaceuticals and the Biotechnology Innovation Organization. Steve Holtzman is president, CEO and board member of Decibel Therapeutics, and on the board of Molecular Partners. Ron Cohen is president and CEO of Acorda Therapeutics and a board member of VBL Therapeutics. Jeremy Levin is an officer at Ovid Therapeutics and on the board of Lundbeck A/S, Biocon Limited and ZappRX.
Issue or Number:10
Record Number:CaltechAUTHORS:20181024-150608861
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:90404
Deposited By: Tony Diaz
Deposited On:25 Oct 2018 17:02
Last Modified:16 Nov 2021 03:32

Repository Staff Only: item control page